Literature DB >> 19618120

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

H Quon1, A Hasbini, J Cougnard, L Djafari, C Lacroix, B Abdulkarim.   

Abstract

According to World Health Organization (WHO) and Daumas-Duport grading systems, progression of oligodendrogliomas (ODGs) to a higher grade (WHO grade III, grade B) is associated with increased angiogenesis. Based on multivariate assessment of molecular, pathological, and radiological parameters, we further assessed the influence of tumor angiogenesis on tumor progression and patient survival. Patients with a diagnosis of ODG, consecutively treated in a single institution, were reviewed and reclassified according to WHO and Daumas-Duport grading systems. MRI scans were reviewed to assess contrast enhancement and necrosis. Tissue sections were used for pathology review and to evaluate immunostaining of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGF-R), Ki-67, and CD34. Multivariate analysis was performed to assess the impact of tumor angiogenesis-related pathological and radiological factors on patient survival. One hundred thirty-four patients with pure ODG were included in this study. Multivariate analysis identified four independent poor prognostic factors: necrosis, absence of seizure, increased vascularization, and age >55 years. A subgroup of patients with tumor necrosis, increased vascularization, and absence of seizures had a significantly worse outcome than predicted, with a median overall survival of 14.2 months. VEGF expression was significantly higher in this subgroup and correlated with disease progression regardless of histologic grade. Based on the presence of radiological or pathological necrosis, contrast enhancement or endothelial hyperplasia, and absence of seizures, a high risk group of ODG can be identified with significantly worse overall survival. Also, VEGF over-expression in ODG constitutes an early marker for predicting tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618120     DOI: 10.1007/s11060-009-9961-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

Authors:  D Fortin; G J Cairncross; R R Hammond
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

3.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

4.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

5.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 6.  Oligodendroglioma: pathology and molecular biology.

Authors:  Herbert H Engelhard; Ana Stelea; Elizabeth J Cochran
Journal:  Surg Neurol       Date:  2002-08

7.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

9.  Cerebral oligodendroglioma: prognostic factors and life history.

Authors:  P Celli; I Nofrone; L Palma; G Cantore; A Fortuna
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

10.  Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

Authors:  A S Chan; S Y Leung; M P Wong; S T Yuen; N Cheung; Y W Fan; L P Chung
Journal:  Am J Surg Pathol       Date:  1998-07       Impact factor: 6.394

View more
  6 in total

1.  A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging.

Authors:  Yaoling Liu; Kang Yang; X U Sun; Xinyu Li; Minghai Wei; Xiang'en Shi; Ningwei Che; Jian Yin
Journal:  Exp Ther Med       Date:  2015-08-10       Impact factor: 2.447

2.  Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma.

Authors:  Daniel Ciznadija; Yuhui Liu; Stephanie M Pyonteck; Eric C Holland; Andrew Koff
Journal:  Cancer Res       Date:  2011-08-15       Impact factor: 12.701

3.  Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration.

Authors:  Steven Maltby; Spencer Freeman; Matthew J Gold; Jennifer H E Baker; Andrew I Minchinton; Michael R Gold; Calvin D Roskelley; Kelly M McNagny
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

4.  Genetic alterations of IDH1 and Vegf in brain tumors.

Authors:  Silvia Veganzones; Virginia de la Orden; Lucía Requejo; Beatriz Mediero; María Luisa González; Náyade Del Prado; Carmen Rodríguez García; Raquel Gutiérrez-González; Alvaro Pérez-Zamarrón; Armando Martínez; Marisa L Maestro; Horacio Mario Zimman; Anna González-Neira; Jesús Vaquero; Gregorio Rodríguez-Boto
Journal:  Brain Behav       Date:  2017-08-01       Impact factor: 2.708

5.  Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway.

Authors:  Jason T Huse; Matija Snuderl; David T W Jones; Carole D Brathwaite; Nolan Altman; Ehud Lavi; Richard Saffery; Alexandra Sexton-Oates; Ingmar Blumcke; David Capper; Matthias A Karajannis; Ryma Benayed; Lukas Chavez; Cheddhi Thomas; Jonathan Serrano; Laetitia Borsu; Marc Ladanyi; Marc K Rosenblum
Journal:  Acta Neuropathol       Date:  2016-11-03       Impact factor: 17.088

6.  Vasculogenic Mimicry Formation Predicts Tumor Progression in Oligodendroglioma.

Authors:  Jing Xie; Xue Kong; Wei Wang; Yuan Li; Mengyu Lin; Heng Li; Jingjing Chen; Wenchao Zhou; Jie He; Haibo Wu
Journal:  Pathol Oncol Res       Date:  2021-08-18       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.